Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
Reyes Maria Martín‐Rojas, Ignacio Gómez‐Centurión, Rebeca Bailén, Mariana Bastos‐Oreiro, Francisco Díaz‐Crespo, Diego Carbonell, Rafael Correa‐Rocha, Marjorie Pion, Cristina Muñoz, Milagros Sancho, Isabel Fernández, Gillen Oarbeascoa, Ana Pérez‐Corral, Carolina Martínez‐Laperche, Javier Anguita, Ismael Buño, Javier Menárguez, José L. Díez‐Martín, Mi Kwon
Abstract
Chimeric antigen receptor (CAR) T cell-related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with poor prognosis and a challenging diagnosis. The establishment of specific diagnosis criteria is essential, and the combination of several techniques for CAR T-cell follow-up, allows a more precise management of this complication.
Topics & Concepts
Macrophage activation syndromeMedicineHemophagocytic lymphohistiocytosisCytokine release syndromeChimeric antigen receptorImmunologyComplicationPerforinAntigenImmunotherapyInternal medicineImmune systemCD8DiseaseArthritisCAR-T cell therapy researchAutoimmune and Inflammatory Disorders ResearchImmune Cell Function and Interaction